BRPI0414450A - derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica - Google Patents

derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica

Info

Publication number
BRPI0414450A
BRPI0414450A BRPI0414450-3A BRPI0414450A BRPI0414450A BR PI0414450 A BRPI0414450 A BR PI0414450A BR PI0414450 A BRPI0414450 A BR PI0414450A BR PI0414450 A BRPI0414450 A BR PI0414450A
Authority
BR
Brazil
Prior art keywords
compounds
substituted
ligands
phenyl
nicotinically
Prior art date
Application number
BRPI0414450-3A
Other languages
English (en)
Inventor
Tao Li
Anwer Basha
William H Bunnelle
Michael J Dart
Megan E Gallagher
Jianguo Ji
Jennifer M Pace
Keith B Ryther
Karin R Tietje
Kathleen H Mortell
Diana L Nersesian
Michael R Schrimpf
Original Assignee
Abbott Laboratoires
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratoires filed Critical Abbott Laboratoires
Publication of BRPI0414450A publication Critical patent/BRPI0414450A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE DIAZABICICLOALCANO SUBSTITUìDOS COMO LIGANDOS NOS RECEPTORES DE ALFA 7 ACETILCOLINA NICOTìNICA". Compostos da fórmula (1) Z Ar~ 1~ Ar~ 2~ onde Z é uma amina diazabicíclica, Ar~ 1~ é um anel aromático com 5 ou 6 membros, e Ar~ 2~ é escolhido do grupo consistindo de um anel heteroarila de 5 ou 6 membros, substituído ou insubstituido; um anel heteroarila bicíclico substituído ou insubstituido; 3,4 (metilenodioxi)fenila; carbazolila; tetrahidrocarbazolila; naftila; e fenila; onde a fenila é substituída por 0, 1, 2, ou 3 substituintes nas posições meta ou para . Os compostos são úteis no tratamento de condições ou distúrbios evitados ou melhorados por ligandos <244>7 nAChR. Também são apresentadas composições farmacêuticas compreendendo compostos da fórmula (I), e métodos para o uso de tais compostos e composições.
BRPI0414450-3A 2003-09-19 2004-09-17 derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica BRPI0414450A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/666,884 US20050065178A1 (en) 2003-09-19 2003-09-19 Substituted diazabicycloakane derivatives
PCT/US2004/030735 WO2005028477A1 (en) 2003-09-19 2004-09-17 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors

Publications (1)

Publication Number Publication Date
BRPI0414450A true BRPI0414450A (pt) 2006-11-14

Family

ID=34313215

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414450-3A BRPI0414450A (pt) 2003-09-19 2004-09-17 derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica

Country Status (13)

Country Link
US (1) US20050065178A1 (pt)
EP (2) EP2316836A1 (pt)
JP (1) JP2007521323A (pt)
KR (1) KR20060109428A (pt)
CN (1) CN101189233A (pt)
AU (2) AU2004274492B2 (pt)
BR (1) BRPI0414450A (pt)
CA (1) CA2538789A1 (pt)
IL (1) IL174400A0 (pt)
NZ (1) NZ545789A (pt)
TW (1) TW200526667A (pt)
WO (1) WO2005028477A1 (pt)
ZA (1) ZA200602274B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AU2005286647A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
ATE493415T1 (de) * 2004-10-20 2011-01-15 Neurosearch As Neue diazabizyklische arylderivate und medizinische verwendung dafür
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
US7531617B2 (en) * 2005-12-21 2009-05-12 E. I. Du Pont De Nemours And Company Continuous process for producing poly(trimethylene terephthalate)
US7524921B2 (en) * 2005-12-21 2009-04-28 E. I. Du Pont De Nemours And Company Continuous manufacture of poly(trimethylene terephthalate)
US7504474B2 (en) * 2005-12-21 2009-03-17 E. I. Du Pont De Nemours And Company Poly(trimethylene therephthalate) continuous manufacturing process
CA2659762A1 (en) * 2006-06-27 2008-01-03 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
EP2041085A1 (en) * 2006-06-27 2009-04-01 Abbott Laboratories Pyrrole derivatives and their methods of use
EP2049110B1 (en) * 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
WO2009067586A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted diazabicycloalkane derivatives
WO2009067579A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011511800A (ja) * 2008-02-07 2011-04-14 アボット・ラボラトリーズ 正のアロステリックな修飾物質としてのアミド誘導体およびこれらの使用方法
US7786171B2 (en) * 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
FR2937641A1 (fr) * 2008-10-28 2010-04-30 Sanofi Aventis Derives d'urees de tropane, leur preparation et leur application en therapeutique
WO2010083444A1 (en) 2009-01-15 2010-07-22 Anvyl, Llc Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
AU2010262643B2 (en) * 2009-06-19 2015-02-19 Abbvie Inc. Diazahomoadamantane derivatives and methods of use thereof
US8796297B2 (en) * 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5847087B2 (ja) 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
BR112013032044A2 (pt) 2011-06-30 2016-12-13 Toray Industries antiprurítico
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
ES2776996T3 (es) 2011-10-20 2020-08-03 Novartis Ag Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7
ES2595240T3 (es) 2012-07-09 2016-12-28 Lupin Limited Derivados de tetrahidroquinazolinona como inhibidores de PARP
CN102977105A (zh) * 2012-11-30 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 3（甲基），7-二氮杂双环辛烷的合成
CN104837499B (zh) 2012-12-11 2018-02-23 诺华有限公司 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014165090A1 (en) * 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
US11332447B2 (en) * 2018-05-24 2022-05-17 Bayer Aktiengesellschaft Method for producing halogenated N-arylpyrazoles
WO2020100011A1 (en) 2018-11-14 2020-05-22 Janssen Pharmaceutica Nv Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
PH12022550295A1 (en) 2019-08-07 2022-11-21 Janssen Pharmaceutica Nv Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079391T3 (es) 1989-04-17 1996-01-16 Bayer Ag Procedimiento para la obtencion de 2,7-diazabiciclo(3.3.0)octanos.
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
MY117098A (en) * 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
ES2305373T3 (es) * 1999-01-29 2008-11-01 Abbott Laboratories Derivados diazabiciclicos como ligandos del receptor nicotinico de la acetilcolina.
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6815438B2 (en) * 1999-12-14 2004-11-09 Neurosearch A/S Heteroaryl-diazabicycloalkanes
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
JP2003534344A (ja) * 2000-05-25 2003-11-18 ターガセプト，インコーポレイテッド ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン
MXPA02010875A (es) 2000-05-31 2003-04-22 Aventis Pharma Gmbh Compuestos de esteres y acidos de ariloxi.
NZ522793A (en) * 2000-07-04 2005-02-25 Neurosearch As Aryl and heteroaryl diazabicycloalkanes, their preparation and use
CA2439415C (en) * 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
DE60203007T2 (de) * 2001-06-01 2005-07-07 Neurosearch A/S Heteroaryl-diazabicycloalkanderivaten als cns-modulatoren
MXPA04010966A (es) * 2002-05-07 2005-01-25 Neurosearch As Derivados novedosos de biarilo diazabiciclico.
DE10232572A1 (de) * 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate

Also Published As

Publication number Publication date
EP1664045A1 (en) 2006-06-07
NZ545789A (en) 2010-03-26
WO2005028477A1 (en) 2005-03-31
AU2004274492A1 (en) 2005-03-31
CA2538789A1 (en) 2005-03-31
US20050065178A1 (en) 2005-03-24
CN101189233A (zh) 2008-05-28
ZA200602274B (en) 2007-11-28
EP2316836A1 (en) 2011-05-04
AU2010202299A1 (en) 2010-06-24
JP2007521323A (ja) 2007-08-02
KR20060109428A (ko) 2006-10-20
IL174400A0 (en) 2006-08-01
TW200526667A (en) 2005-08-16
AU2004274492B2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
BRPI0414450A (pt) derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica
BRPI0612141A2 (pt) derivados de quinuclidina substituìdos com biciclo-heterociclos fundidos
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR0208907A (pt) Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto.
BR0010391A (pt) Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto
DE60226875D1 (de) Orthosubstituierte arylamide zur bekämpfung von wirbellosen schädlingen
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
TR200002015T2 (tr) Protein tirosin kinaz inhibitörleri olarak bisiklik heteroaromatik bileşikler.
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
ATE301653T1 (de) Pyrazolopyridine
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BR9914370A (pt) Derivados de tetraidrobenzazepina úteis comomoduladores de receptores para a dopamina d3(agentes antipsicóticos)
EA199800882A1 (ru) Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.